News
Structure-based drug design articles from across Nature Portfolio Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound ...
Molecular biophysics is the study of the physical principles governing biomolecular systems. It seeks to explain biological function in terms of molecular structure, dynamics and organization ...
PCSK9 inhibitors -- monoclonal antibodies alirocumab (Praluent) and evolocumab (Repatha) and small interfering RNA agent inclisiran (Leqvio) -- have class IIb recommendation to add on to the ...
PCSK9 inhibitors -- alirocumab (Praluent), evolocumab (Repatha), and inclisiran (Leqvio) -- are injections that keep LDL receptors free to bind to LDL cholesterol and keep it out of the blood ...
AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, playing catch-up with rival MSD.
Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), both antibodies dosed monthly, and Novartis' small interfering RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results